A Phase 1b Study of Transforming Growth Factor-Beta Receptor I Inhibitor Galunisertib in Combination With Sorafenib in Japanese Patients With Unresectable Hepatocellular Carcinoma
Investigational New Drugs - Netherlands
doi 10.1007/s10637-018-0636-3
Full Text
Open PDFAbstract
Available in full text
Date
July 11, 2018
Authors
Publisher
Springer Science and Business Media LLC